ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 3 for:    perifosine AND colorectal

Placebo-Controlled Study of Perifosine + Single Agent Chemotherapy for Metastatic Cancer Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00398879
Recruitment Status : Completed
First Posted : November 14, 2006
Last Update Posted : March 14, 2018
Sponsor:
Information provided by (Responsible Party):
AEterna Zentaris

Brief Summary:

This is an exploratory phase 2, randomized placebo-controlled trial with stratification for disease and chemotherapy type. The study is subsequently closed to enrollment in all arms except patients with metastatic colorectal cancer which would be randomized to either capecitabine plus perifosine or capecitabine alone.

The effects of perifosine may be manifested by increased time to progression, tumor regression reflected in partial or complete responses, or a combination of these outcomes. The primary goal of this trial is to obtain a preliminary and objective assessment of the effects of perifosine on time to progression.


Condition or disease Intervention/treatment Phase
Colon Cancer Drug: Perifosine Drug: Capecitabine Other: Perifosine Placebo Phase 2

Detailed Description:

This is an exploratory phase 2, randomized placebo-controlled trial with stratification for disease and chemotherapy type. If there is any evidence of improved time to progression in any tumor type with any of the drugs to be evaluated, the initial study or component(s) of the study will be expanded to increase the certainty that this is an effect of perifosine. If there is compelling evidence of benefit from this study, a phase 3 trial will be conducted to obtain proof of principle.

Primary Study Objectives:

To determine the time to tumor progression when receiving single agent chemotherapy (capecitabine) in combination with perifosine in comparison to patients receiving single agent chemotherapy (capecitabine) alone (i.e., with placebo).

Secondary Study Objectives:

  • To determine the toxicity of single agent chemotherapy in combination with perifosine.
  • To compare the time to progression of chemotherapy in combination with placebo to historical experience.
  • Overall survival will also be evaluated.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 381 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: A Randomized Placebo-Controlled Study of Perifosine in Combination With Single Agent Chemotherapy for Metastatic Cancer Patients
Study Start Date : August 2005
Actual Primary Completion Date : December 2010
Actual Study Completion Date : October 2011

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: Arm 1: Perifosine + Capecitabine
Perifosine 50 mg/d qd + Capecitabine 825 mg/m^2 BID days 1 - 14 q 3 weeks until progression
Drug: Perifosine
Perifosine 50 mg/d qd
Other Names:
  • D-21266
  • KRX-0401
Drug: Capecitabine
Capecitabine 825 mg/m^2 BID days 1 - 14 q 3 weeks
Placebo Comparator: Arm 2: Perifosine Placebo + Capecitabine
Perifosine Placebo 50 mg/d qd + Capecitabine 825 mg/m^2 BID days 1 - 14 q 3 weeks until progression
Drug: Capecitabine
Capecitabine 825 mg/m^2 BID days 1 - 14 q 3 weeks
Other: Perifosine Placebo
Placebo to Perifosine 50 mg/d qd
Other Name: placebo



Primary Outcome Measures :
  1. Effects of perifosine on time to progression [ Time Frame: Every 12 weeks ]
    Time to progression will be measured from the first day of study drug until progression.


Secondary Outcome Measures :
  1. Toxicity [ Time Frame: Every 12 weeks ]
    Determination of the toxicity of single agent chemotherapy in combination with perifosine. Toxicity evaluation is to be performed throughout the study.

  2. Comparison of time to progression to historical experience [ Time Frame: Every 12 weeks ]
    To compare the time to progression of chemotherapy in combination with placebo to historical experience.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. In the opinion of the treating physician, treatment with one of the following regimens should represent an appropriate treatment for the patient.

    - Capecitabine 825 mg/m2 BID days 1 - 14 q 3 weeks

  2. Patients should have a histologically or cytologically confirmed diagnosis of colorectal cancer.
  3. Patients must have received at least one but no more than two prior chemotherapy regimen(s) for the treatment of metastatic or recurrent disease.
  4. ECOG performance status 0 or 1.

    • Leukocytes >= 4,000/μL
    • absolute neutrophil count >= 1,500/ μL
    • platelets >= 100,000/ μL
    • HCT > 28% (with or without growth factor support)
    • Creatinine <= 2.5 mg/dl
    • total bilirubin < 1.5 x upper limit of normal
    • transaminase < 2.5 x upper limit of normal
  5. Patients must have recovered from acute toxicity—excluding alopecia—related to prior therapy, including surgery or radiotherapy.
  6. Patients with brain metastases may be admitted, provided the disease has been treated and been stable for 2 months.
  7. Patients must have ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

  1. Patients receiving any other investigational agents or devices.
  2. History of allergic reactions attributed to compounds of similar chemical or biologic composition to perifosine (miltefosine or edelfosine).
  3. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, psychiatric illness, or social situations that would limit compliance with study requirements.
  4. HIV-positive patients receiving combination anti-retroviral therapy are excluded from the study due to potential pharmacokinetic interactions with perifosine.
  5. Patients with a history of unstable or newly diagnosed angina pectoris, recent myocardial infarction (within 6 months of enrollment), or New York Heart Assoc. class II - IV congestive heart failure.
  6. Female patients who are pregnant or lactating are ineligible.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00398879


  Show 49 Study Locations
Sponsors and Collaborators
AEterna Zentaris
Investigators
Study Chair: Craig Henderson, MD Online Collaborative Oncology Group

Publications of Results:
Responsible Party: AEterna Zentaris
ClinicalTrials.gov Identifier: NCT00398879     History of Changes
Other Study ID Numbers: Perifosine 211
First Posted: November 14, 2006    Key Record Dates
Last Update Posted: March 14, 2018
Last Verified: February 2012

Keywords provided by AEterna Zentaris:
Capecitabine

Additional relevant MeSH terms:
Neoplasm Metastasis
Neoplastic Processes
Neoplasms
Pathologic Processes
Capecitabine
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents